Trial Profile
A PHASE 1B, RANDOMIZED, CONTROLLED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY JAPANESE ADULTS 18 TO 49 YEARS OF AGE
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Dec 2020
Price :
$35
*
At a glance
- Drugs Pneumococcal 20-valent conjugate vaccine (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
- 25 Oct 2020 Results presented at the IDWeek 2020
- 23 Apr 2019 Status changed from active, no longer recruiting to completed.
- 25 Mar 2019 Planned End Date changed from 25 Mar 2019 to 28 Mar 2019.